ShareDunia

Capsule sized Insights on Indian Share market & Business

SPARC Licenses Commercialization Rights of ElepsiaTM XR to Tripoint Therapeutics

Sun Pharma Advanced Research Company Ltd. (SPARC) today announced the grant of an exclusive license

Sun Pharma Advanced Research Company Ltd. (SPARC) today announced the grant of an exclusive license to Tripoint Therapeutics LLC, USA (Tripoint) to commercialize ElepsiaTM XR 1000 mg and ElepsiaTM XR 1500 mg tablets in the USA.

Under terms of the license agreement, SPARC will be eligible to receive tiered royalties ranging from 15% to 50% on net sales. Tripoint will be responsible for all US regulatory submissions and payment of annual PDUFA fees for ElepsiaTM XR 1000 mg and ElepsiaTM XR 1500 mg.

The initial term of the agreement shall be 5 years and may be further extended as per mutual agreement between the parties.

Loading